Previous 10 | Next 10 |
Biohaven Pharmaceuticals press release ( NYSE: BHVN ): Q2 Non-GAAP EPS of -$3.82 misses by $1.57 . Revenue of $194M (+108.8% Y/Y) misses by $16.6M . The Company remains on track to meet full year 2022 net product sales guidance of $825 - $900 million. For...
Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments PR Newswire Antitrust approvals have been granted by the relevant governing authorities, including the Federal Trade Commission ("FTC"), with respect to the previously annou...
SMID cap growth stocks have entered bear market territory, pressured by significant multiple compression from higher interest rates and unfolding economic deceleration. The Strategy underperformed in a difficult market, with declines most pronounced among several long-term holdings in...
American Migraine Foundation Survey Shows Nearly All People with Migraine and Healthcare Professionals Believe Migraine and Mental Health Significantly Impact Each Other PR Newswire 84% of people with migraine (PwM) and 92% of healthcare professionals (HCPs) agree th...
Small cap growth stocks have entered bear market territory, pressured by significant multiple compression from higher interest rates and unfolding economic deceleration. The Strategy underperformed in a difficult market, with declines most pronounced among several long-term holdings i...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Following the rapid vaccination drives across the world last year, the demand for Covid-19 vaccines is declining. However, booster doses targeting new subvariants are expected to drive sales for coronavirus stocks in the da...
Biohaven Pharmaceutical ( NYSE: BHVN ) said it enrolled the first patient in a phase 3 of taldefgrobep alfa in spinal muscular atrophy (SMA). SMA is an inherited disorder characterized by loss of nerve cells leading to muscle weakness over time. The company said ta...
Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA) PR Newswire NEW HAVEN, Conn. , July 7, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a commercial-stage biopharmaceutical ...
Biohaven and Vigeo Now Enrolling in GBM AGILE, Registrational Phase 2-3 Adaptive Platform Trial to Evaluate Interventions for Patients With Glioblastoma Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and Vige...
Pure play COVID-19 vaccine makers closed the 1H 2022 as some of the worst performers in the beaten-down biotech space amid concerns over how the group, once a pandemic favorite, could sustain growth as COVID impact wanes. The selloff, worse than the ~33% decline among biotech stocks...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-07-24 06:30:09 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for BHVN on July 24, 2024 04:48AM ET. BHVN was trading at $37.81 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy reco...
2024-07-24 06:00:03 ET Terence Flynn from Morgan Stanley issued a price target of $58.00 for BHVN on 2024-07-24 04:48:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $37.81. The overall price target consensus is at $4...
2024-07-20 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...